QuidelOrtho Corporation
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.73B | $2.78B | $3.00B | $1.70B | $1.66B |
| Cost of Revenue | $1.46B | $1.50B | $1.50B | $420.3M | $305.4M |
| Gross Profit | $1.27B | $1.29B | $1.50B | $1.28B | $1.36B |
| Gross Margin | 46.7% | 46.2% | 49.9% | 75.3% | 81.6% |
| Operating Expenses | |||||
| Research & Development | $186.2M | $218.7M | $245.0M | $95.7M | $84.3M |
| SG&A Expense | $746.3M | $766.8M | $763.2M | $239.6M | $180.7M |
| Operating Income | $-919.2M | $-1.96B | $139.1M | $906.0M | $1.06B |
| Operating Margin | -33.7% | -70.5% | 4.6% | 53.3% | 63.8% |
| Interest Expense | — | — | — | — | — |
| Pretax Income | $-1.11B | $-2.13B | $-29.1M | $900.3M | $1.04B |
| Income Tax Expense | $24.1M | $-79.5M | $-19.0M | $196.1M | $230.0M |
| Net Income | $-1.13B | $-2.05B | $-10.1M | $704.2M | $810.3M |
| Net Margin | -41.5% | -73.7% | -0.3% | 41.5% | 48.8% |
| EPS (Basic) | $-16.69 | $-30.54 | $-0.15 | $16.74 | $19.24 |
| EPS (Diluted) | $-16.69 | $-30.54 | $-0.15 | $16.43 | $18.60 |
| Shares Outstanding (Basic) | 67.8M | 67.2M | 66.8M | 42.1M | 42.1M |
| Shares Outstanding (Diluted) | 67.8M | 67.2M | 66.8M | 42.9M | 43.6M |
| Dividends Per Share | — | — | — | — | — |